{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T13:49:12Z","timestamp":1790689752235,"version":"4.1.0"},"reference-count":68,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003329","name":"Ministerio de Econom\u00eda y Competitividad of Spain","doi-asserted-by":"publisher","award":["CTQ2016-77270-R"],"award-info":[{"award-number":["CTQ2016-77270-R"]}],"id":[{"id":"10.13039\/501100003329","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Consejer\u00eda de Econom\u00eda y Conocimiento-Junta de Andaluc\u00eda","award":["FQM-345"],"award-info":[{"award-number":["FQM-345"]}]},{"DOI":"10.13039\/501100001691","name":"JSPS KAKENHI","doi-asserted-by":"publisher","award":["JP17K08362"],"award-info":[{"award-number":["JP17K08362"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Progetto Dipartimenti di Eccellenza","award":["2018\u20132022"],"award-info":[{"award-number":["2018\u20132022"]}]},{"DOI":"10.13039\/501100003056","name":"Ente Cassa di Risparmio di Firenze","doi-asserted-by":"publisher","award":["2016\/0845"],"award-info":[{"award-number":["2016\/0845"]}],"id":[{"id":"10.13039\/501100003056","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003056","name":"Ente Cassa di Risparmio di Firenze","doi-asserted-by":"publisher","award":["2018.0942"],"award-info":[{"award-number":["2018.0942"]}],"id":[{"id":"10.13039\/501100003056","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.ejmech.2020.112173","type":"journal-article","created":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T16:43:28Z","timestamp":1582217008000},"page":"112173","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["Synthesis of multimeric pyrrolidine iminosugar inhibitors of human \u03b2-glucocerebrosidase and \u03b1-galactosidase A: First example of a multivalent enzyme activity enhancer for Fabry disease"],"prefix":"10.1016","volume":"192","author":[{"given":"Macarena","family":"Mart\u00ednez-Bail\u00e9n","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana T.","family":"Carmona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Cardona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla","family":"Matassini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Goti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moemi","family":"Kubo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inmaculada","family":"Robina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio J.","family":"Moreno-Vargas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2020.112173_bib1a","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1039\/b901828j","article-title":"Maximising multivalency effects in protein\u2013carbohydrate interactions","volume":"7","author":"Pieters","year":"2009","journal-title":"Org. Biomol. Chem."},{"key":"10.1016\/j.ejmech.2020.112173_bib1b","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1021\/cr500303t","article-title":"Glycomimetics versus multivalent glycoconjugates for the design of high affinity lectin ligands","volume":"115","author":"Cecioni","year":"2015","journal-title":"Chem. Rev."},{"key":"10.1016\/j.ejmech.2020.112173_bib1c","doi-asserted-by":"crossref","first-page":"3275","DOI":"10.1039\/C6CS00165C","article-title":"Organizing multivalency in carbohydrate recognition","volume":"45","author":"M\u00fcller","year":"2016","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.ejmech.2020.112173_bib1d","doi-asserted-by":"crossref","first-page":"9894","DOI":"10.1039\/C5OB01405K","article-title":"Emerging trends in enzyme inhibition by multivalent nanoconstructs","volume":"13","author":"Kanfar","year":"2015","journal-title":"Org. Biomol. Chem."},{"key":"10.1016\/j.ejmech.2020.112173_bib2","doi-asserted-by":"crossref","first-page":"7488","DOI":"10.1002\/anie.200902490","article-title":"What is cooperativity?","volume":"48","author":"Hunter","year":"2009","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.ejmech.2020.112173_sref10","unstructured":"(For reviews, see):"},{"key":"10.1016\/j.ejmech.2020.112173_bib3a","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1002\/cbic.201402026","article-title":"The multivalent effect in glycosidase inhibition: a new, rapidly emerging topic in glycoscience","volume":"15","author":"Compain","year":"2014","journal-title":"Chembiochem"},{"key":"10.1016\/j.ejmech.2020.112173_bib3b","doi-asserted-by":"crossref","first-page":"11616","DOI":"10.1002\/chem.201402537","article-title":"Multivalent inhibitors for carbohydrate-processing enzymes: beyond the \u201clock-and-key\u201d concept","volume":"20","author":"Gouin","year":"2014","journal-title":"Chem. Eur J."},{"key":"10.1016\/j.ejmech.2020.112173_bib3c","doi-asserted-by":"crossref","first-page":"5050","DOI":"10.1039\/C5NJ00462D","article-title":"Synthesis and biological properties of multivalent iminosugars","volume":"30","author":"Zelli","year":"2015","journal-title":"New J. Chem."},{"key":"10.1016\/j.ejmech.2020.112173_bib3d","doi-asserted-by":"crossref","first-page":"5407","DOI":"10.1016\/j.tetlet.2016.10.080","article-title":"Are enzymes sensitive to the multivalent effect? Emerging evidence with glycosidases","volume":"57","author":"Matassini","year":"2016","journal-title":"Tetrahedron Lett."},{"key":"10.1016\/j.ejmech.2020.112173_bib4a","doi-asserted-by":"crossref","first-page":"14585","DOI":"10.1002\/chem.201703011","article-title":"Mechanistic insight into the binding of multivalent pyrrolidines to \u03b1-mannosidases","volume":"23","author":"Mirabella","year":"2017","journal-title":"Chem. Eur J."},{"key":"10.1016\/j.ejmech.2020.112173_bib4b","doi-asserted-by":"crossref","first-page":"5151","DOI":"10.1002\/chem.201600338","article-title":"Minosugar-cyclopeptoid conjugates raise multivalent effect in glycosidase inhibition at unprecedented high levels","volume":"22","author":"Lepage","year":"2016","journal-title":"Chem. Eur J."},{"key":"10.1016\/j.ejmech.2020.112173_bib4c","doi-asserted-by":"crossref","first-page":"13825","DOI":"10.1002\/chem.201102266","article-title":"The multivalent effect in glycosidase inhibition: probing the influence of architectural parameters with cyclodextrin-based iminosugar click clusters","volume":"17","author":"Decroocq","year":"2011","journal-title":"Chem. Eur J."},{"key":"10.1016\/j.ejmech.2020.112173_bib4d","doi-asserted-by":"crossref","first-page":"5753","DOI":"10.1002\/anie.201002802","article-title":"Glycosidase inhibition with fullerene iminosugar balls: a dramatic multivalent effect","volume":"49","author":"Compain","year":"2010","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.ejmech.2020.112173_bib5","doi-asserted-by":"crossref","first-page":"8002","DOI":"10.1002\/anie.201801202","article-title":"Structural basis of outstanding multivalent effects in Jack bean \u03b1-mannosidase inhibition","volume":"57","author":"Howard","year":"2018","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.ejmech.2020.112173_bib6a","doi-asserted-by":"crossref","first-page":"16791","DOI":"10.1002\/chem.201303158","article-title":"Fullerene-sp2-Iminosugar balls as multimodal ligands for lectins and glycosidases: a mechanistic hypothesis for the inhibitory multivalent effect","volume":"19","author":"R\u00edsquez-Cuadro","year":"2013","journal-title":"Chem. Eur J."},{"key":"10.1016\/j.ejmech.2020.112173_bib6b","doi-asserted-by":"crossref","first-page":"6295","DOI":"10.1002\/chem.201700470","article-title":"The impact of heteromultivalency in lectin recognition and glycosidase inhibition: an integrated mechanistic study","volume":"23","author":"Garc\u00eda-Moreno","year":"2017","journal-title":"Chem. Eur J."},{"key":"10.1016\/j.ejmech.2020.112173_bib6c","doi-asserted-by":"crossref","first-page":"11450","DOI":"10.1002\/chem.201601673","article-title":"Potent glycosidase inhibition with heterovalent fullerenes: unveiling the binding modes triggering multivalent inhibition","volume":"22","author":"Abell\u00e1n Flos","year":"2016","journal-title":"Chem. Eur J."},{"key":"10.1016\/j.ejmech.2020.112173_bib7","doi-asserted-by":"crossref","first-page":"9022","DOI":"10.1002\/chem.201701756","article-title":"Multivalency to inhibit and discriminate hexosaminidases","volume":"23","author":"Alv\u00e1rez-Dorta","year":"2017","journal-title":"Chem. Eur J."},{"key":"10.1016\/j.ejmech.2020.112173_bib8","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1002\/chem.201705600","article-title":"Giant glycosidase inhibitors: first- and second-generation fullerodendrimers with a dense iminosugar shell","volume":"24","author":"Nierengarten","year":"2018","journal-title":"Chem. Eur J."},{"key":"10.1016\/j.ejmech.2020.112173_bib9a","doi-asserted-by":"crossref","first-page":"64847","DOI":"10.1039\/C6RA15806D","article-title":"Evidence for a multivalent effect in inhibition of sulfatases involved in lysosomal storage disorders (LSDs)","volume":"6","author":"D\u2019Adamio","year":"2016","journal-title":"RSC Adv."},{"key":"10.1016\/j.ejmech.2020.112173_bib9b","doi-asserted-by":"crossref","first-page":"8604","DOI":"10.1039\/C8OB02587H","article-title":"Multimerization of DAB-1 onto Au GNPs affords new potent and selective N-acetylgalactosamine-6-sulfatase (GALNS) inhibitors","volume":"16","author":"Matassini","year":"2018","journal-title":"Org. Biomol. Chem."},{"key":"10.1016\/j.ejmech.2020.112173_bib10","article-title":"Multivalent effect in glycosidase inhibition: the end of the beginning","volume":"19","author":"Compain","year":"2019","journal-title":"Chem. Rec."},{"key":"10.1016\/j.ejmech.2020.112173_bib11","doi-asserted-by":"crossref","first-page":"6428","DOI":"10.1039\/C7TB00860K","article-title":"Multivalency as an action principle in multimodal lectin recognition and glycosidase inhibition: a paradigm shift driven by carbon-based glyconanomaterials","volume":"5","author":"Ortiz Mellet","year":"2017","journal-title":"J.\u00a0Mater. Chem. B"},{"key":"10.1016\/j.ejmech.2020.112173_bib12a","doi-asserted-by":"crossref","first-page":"5914","DOI":"10.1021\/jacs.7b13003","article-title":"\u03b2-Glucocerebrosidase modulators promote dimerization of \u03b2-glucocerebrosidase and reveal an allosteric binding site","volume":"140","author":"Zheng","year":"2018","journal-title":"J.\u00a0Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2020.112173_bib12b","doi-asserted-by":"crossref","first-page":"3625","DOI":"10.1074\/jbc.M109.060145","article-title":"Catalytic mechanism of human \u03b1-galactosidase","volume":"285","author":"Guce","year":"2010","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2020.112173_bib13","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.expneurol.2017.09.010","article-title":"Insights into the structural biology of Gaucher disease","volume":"298","author":"Smith","year":"2017","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.ejmech.2020.112173_bib14","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.jmb.2004.01.035","article-title":"The molecular defect leading to Fabry disease: structure of human alpha-galactosidase","volume":"337","author":"Garman","year":"2004","journal-title":"J.\u00a0Mol. Biol."},{"key":"10.1016\/j.ejmech.2020.112173_bib15","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/nature13476","article-title":"Sphingolipid lysosomal storage disorders","volume":"510","author":"Platt","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2020.112173_bib16a","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1021\/acschembio.6b00195","article-title":"Pharmacological chaperones: design and development of new therapeutic strategies for the treatment of conformational diseases","volume":"11","author":"Convertino","year":"2016","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.ejmech.2020.112173_bib16b","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1021\/jm301557k","article-title":"Pharmacological chaperones as therapeutics for lysosomal storage diseases","volume":"56","author":"Boyd","year":"2013","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112173_bib16c","doi-asserted-by":"crossref","first-page":"448","DOI":"10.3389\/fphar.2017.00448","article-title":"Pharmaceutical chaperones and proteostasis regulators in the therapy of lysosomal storage disorders: current perspective and future promises","volume":"8","author":"Mohamed","year":"2017","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2020.112173_sref10a","unstructured":"(For reviews, see):"},{"key":"10.1016\/j.ejmech.2020.112173_bib17a","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1039\/C7SC04712F","article-title":"Tuning protein folding in lysosomal storage diseases: the chemistry behind pharmacological chaperones","volume":"9","author":"Pereira","year":"2018","journal-title":"Chem. Sci."},{"key":"10.1016\/j.ejmech.2020.112173_bib17b","doi-asserted-by":"crossref","first-page":"5497","DOI":"10.1039\/C6CC01564F","article-title":"Glycomimetic-based pharmacological chaperones for lysosomal storage disorders: lessons from Gaucher, GM1-gangliosidosis and Fabry diseases","volume":"52","author":"S\u00e1nchez-Fern\u00e1ndez","year":"2016","journal-title":"Chem. Commun."},{"key":"10.1016\/j.ejmech.2020.112173_bib17c","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2174\/157340812800228955","article-title":"The two faces of iminoalditols: powerful inhibitors trigger glycosidase activation","volume":"8","author":"Wrodnigg","year":"2012","journal-title":"Curr. Enzym. Inhib."},{"key":"10.1016\/j.ejmech.2020.112173_bib17d","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1080\/14789450.2016.1174583","article-title":"Progress and potential of non-inhibitory small molecule chaperones for the treatment of Gaucher disease and its implications for Parkinson disease","volume":"13","author":"Jung","year":"2016","journal-title":"Expert Rev. Proteomics"},{"key":"10.1016\/j.ejmech.2020.112173_bib18a","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1039\/C5OB02281A","article-title":"Conformationally-locked C-glycosides: tuning aglycone interactions for optimal chaperone behaviour in Gaucher fibroblasts","volume":"14","author":"Navo","year":"2016","journal-title":"Org. Biomol. Chem."},{"key":"10.1016\/j.ejmech.2020.112173_bib18b","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1021\/jm201633y","article-title":"Rapid assembly of a library of lipophilic iminosugars via the thiol\u2013ene reaction yields promising pharmacological chaperones for the treatment of gaucher disease","volume":"55","author":"Goddard-Borger","year":"2012","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112173_bib18c","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1002\/cbic.201500292","article-title":"Human acid \u03b2-glucosidase inhibition by carbohydrate derived iminosugars: towards new pharmacological chaperones for gaucher disease","volume":"16","author":"Parmeggiani","year":"2015","journal-title":"Chembiochem"},{"key":"10.1016\/j.ejmech.2020.112173_bib18d","doi-asserted-by":"crossref","first-page":"5021","DOI":"10.1016\/j.bmc.2013.06.054","article-title":"Rapid modifications of N-substitution in iminosugars: development of new \u03b2-glucocerebrosidase inhibitors and pharmacological chaperones for Gaucher disease","volume":"21","author":"Cheng","year":"2013","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112173_bib18e","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.biocel.2014.07.017","article-title":"Selective chaperone effect of aminocyclitol derivatives on G202R and other mutant glucocerebrosidases causing Gaucher disease","volume":"54","author":"Serra-Vinardell","year":"2014","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.ejmech.2020.112173_bib18f","doi-asserted-by":"crossref","first-page":"5734","DOI":"10.1021\/jm300063b","article-title":"Discovery, structure\u2013activity relationship, and biological evaluation of noninhibitory small molecule chaperones of glucocerebrosidase","volume":"55","author":"Patnaik","year":"2012","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112173_bib18g","doi-asserted-by":"crossref","first-page":"11696","DOI":"10.1002\/anie.201505147","article-title":"pH-responsive pharmacological chaperones for rescuing mutant glycosidases","volume":"54","author":"Mena-Barrag\u00e1n","year":"2015","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.ejmech.2020.112173_bib18h","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1039\/C5OB02223A","article-title":"Docking study and biological evaluation of pyrrolidine-based iminosugars as pharmacological chaperones for Gaucher disease","volume":"14","author":"Kato","year":"2016","journal-title":"Org. Biomol. Chem."},{"key":"10.1016\/j.ejmech.2020.112173_bib19a","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.carres.2016.03.007","article-title":"Investigation of original multivalent iminosugars as pharmacological chaperones for the treatment of Gaucher disease","volume":"429","author":"Laigre","year":"2016","journal-title":"Carbohydr. Res."},{"key":"10.1016\/j.ejmech.2020.112173_bib19b","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/cbic.201200005","article-title":"Cyclodextrin-based iminosugar click clusters: the first examples of multivalent pharmacological chaperones for the treatment of lysosomal storage disorders","volume":"13","author":"Decroocq","year":"2012","journal-title":"Chembiochem"},{"key":"10.1016\/j.ejmech.2020.112173_bib19c","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1002\/cbic.201300442","article-title":"A\u00a0systematic investigation of iminosugar click clusters as pharmacological chaperones for the treatment of gaucher disease","volume":"15","author":"Joosten","year":"2014","journal-title":"Chembiochem"},{"key":"10.1016\/j.ejmech.2020.112173_bib20a","doi-asserted-by":"crossref","first-page":"9233","DOI":"10.1039\/C9SC03342D","article-title":"\u03b1-D-Gal-cyclophellitol cyclosulfamidate is a Michaelis complex analog that stabilizes therapeutic lysosomal \u03b1-galactosidase A in Fabry disease","volume":"10","author":"Artola","year":"2019","journal-title":"Chem. Sci."},{"key":"10.1016\/j.ejmech.2020.112173_bib20b","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/mt.2011.271","article-title":"Co-administration with the pharmacological chaperone AT1001 increases recombinant human \u03b1-galactosidase A tissue uptake and improves substrate reduction in Fabry mice","volume":"20","author":"Benjamin","year":"2012","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ejmech.2020.112173_bib20c","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s10545-011-9424-3","article-title":"Synergy between the pharmacological chaperone 1-deoxygalactonojirimycin and the human recombinant alpha-galactosidase A in cultured fibroblasts from patients with Fabry disease","volume":"35","author":"Porto","year":"2012","journal-title":"J.\u00a0Inherit. Metab. Dis."},{"key":"10.1016\/j.ejmech.2020.112173_bib21a","doi-asserted-by":"crossref","first-page":"2647","DOI":"10.1002\/cmdc.201402411","article-title":"Iminosugar-based galactoside mimics as inhibitors of galactocerebrosidase: SAR studies and comparison with other lysosomal galactosidases","volume":"9","author":"Biela-Banas","year":"2014","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2020.112173_bib21b","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1021\/cb500143h","article-title":"Molecular basis of 1-deoxygalactonojirimycin arylthiourea binding to human \u03b1-galactosidase A: pharmacological chaperoning efficacy on Fabry disease mutants","volume":"9","author":"Yu","year":"2014","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.ejmech.2020.112173_bib21c","doi-asserted-by":"crossref","first-page":"6514","DOI":"10.1039\/c2cc32065g","article-title":"Tuning glycosidase inhibition through aglycone interactions: pharmacological chaperones for Fabry disease and GM1 gangliosidosis","volume":"48","author":"Aguilar-Moncayo","year":"2012","journal-title":"Chem. Commun."},{"key":"10.1016\/j.ejmech.2020.112173_bib21d","doi-asserted-by":"crossref","first-page":"3790","DOI":"10.1016\/j.bmc.2010.04.048","article-title":"2,5-Dideoxy-2,5-imino-D-altritol as a new class of pharmacological chaperone for Fabry disease","volume":"18","author":"Kato","year":"2010","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112173_bib21e","doi-asserted-by":"crossref","first-page":"4179","DOI":"10.1046\/j.1432-1327.2000.01457.x","article-title":"In\u00a0vitro inhibition and intracellular enhancement of lysosomal alpha-galactosidase A activity in Fabry lymphoblasts by 1-deoxygalactonojirimycin and its derivatives","volume":"267","author":"Asano","year":"2000","journal-title":"Eur. J. Biochem."},{"key":"10.1016\/j.ejmech.2020.112173_bib21f","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.carres.2015.10.009","article-title":"5-Fluoro derivatives of 4-epi-isofagomine as D-galactosidase inhibitors and potential pharmacological chaperones for GM1-gangliosidosis as well as Fabry\u2019s disease","volume":"420","author":"Thonhofer","year":"2016","journal-title":"Carbohydr. Res."},{"key":"10.1016\/j.ejmech.2020.112173_bib22a","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.ejmech.2017.06.055","article-title":"Tuning of \u03b2-glucosidase and \u03b1-galactosidase inhibition by generation and in situ screening of a library of pyrrolidine-triazole hybrid molecules","volume":"138","author":"Mart\u00ednez-Bail\u00e9n","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112173_bib22b","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.bioorg.2019.02.025","article-title":"Exploring substituent diversity on pyrrolidine-aryltriazole iminosugars: structural basis of \u03b2-glucocerebrosidase inhibition","volume":"86","author":"Mart\u00ednez-Bail\u00e9n","year":"2019","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2020.112173_bib23","doi-asserted-by":"crossref","first-page":"103026","DOI":"10.1016\/j.bioorg.2019.103026","article-title":"Structural basis of the inhibition of GH1 \u03b2-glucosidases by multivalent pyrrolidine iminosugars","volume":"89","author":"Mart\u00ednez-Bail\u00e9n","year":"2019","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2020.112173_bib24a","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1002\/1521-3773(20010601)40:11<2004::AID-ANIE2004>3.0.CO;2-5","article-title":"Click chemistry: diverse chemical function from a few good reactions","volume":"40","author":"Kolb","year":"2001","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.ejmech.2020.112173_bib24b","doi-asserted-by":"crossref","first-page":"2596","DOI":"10.1002\/1521-3773(20020715)41:14<2596::AID-ANIE2596>3.0.CO;2-4","article-title":"A\u00a0stepwise huisgen cycloaddition process: copper(I)-Catalyzed regioselective \u201cligation\u201d of azides and terminal alkynes","volume":"41","author":"Rostovtsev","year":"2002","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.ejmech.2020.112173_bib24c","doi-asserted-by":"crossref","first-page":"3057","DOI":"10.1021\/jo011148j","article-title":"Peptidotriazoles on solid phase: [1,2,3]-Triazoles by regiospecific copper(I)-Catalyzed 1,3-dipolar cycloadditions of terminal alkynes to azides","volume":"67","author":"Torn\u00f6e","year":"2002","journal-title":"J.\u00a0Org. Chem."},{"key":"10.1016\/j.ejmech.2020.112173_bib25a","doi-asserted-by":"crossref","first-page":"6522","DOI":"10.1021\/acs.orglett.7b03231","article-title":"Synthesis of oligo-(alkyne-triplet)peptide constructs","volume":"19","author":"Stuhr-Hansen","year":"2017","journal-title":"Org. Lett."},{"key":"10.1016\/j.ejmech.2020.112173_bib25b","doi-asserted-by":"crossref","first-page":"4413","DOI":"10.1039\/C3RA43238F","article-title":"Synthesis, H2PO4\u2212 and Pd2+ ion sensing and gold nanoparticle encapsulation of ferrocenyldendrimers by a green chemistry approach","volume":"4","author":"Rajakumar","year":"2014","journal-title":"RSC Adv."},{"key":"10.1016\/j.ejmech.2020.112173_bib26a","doi-asserted-by":"crossref","first-page":"5898","DOI":"10.1039\/C4OB00931B","article-title":"Rapid discovery of potent \u03b1-fucosidase inhibitors by in situ screening of a library of (pyrrolidin-2-yl)triazoles","volume":"12","author":"El\u00edas-Rodr\u00edguez","year":"2014","journal-title":"Org. Biomol. Chem."},{"key":"10.1016\/j.ejmech.2020.112173_bib26b","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.ejmech.2018.04.008","article-title":"Harnessing pyrrolidine iminosugars into dimeric structures for the rapid discovery of divalent glycosidase inhibitors","volume":"151","author":"Carmona","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112173_bib27","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1021\/acsmedchemlett.8b00602","article-title":"Stereoselective synthesis of C-2 alkylated trihydroxypiperidines: novel pharmacological chaperones for gaucher disease","volume":"10","author":"Clemente","year":"2019","journal-title":"ACS Med. Chem. Lett."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523420301409?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523420301409?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T14:08:00Z","timestamp":1759327680000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523420301409"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":68,"alternative-id":["S0223523420301409"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2020.112173","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Synthesis of multimeric pyrrolidine iminosugar inhibitors of human \u03b2-glucocerebrosidase and \u03b1-galactosidase A: First example of a multivalent enzyme activity enhancer for Fabry disease","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2020.112173","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"112173"}}